In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A-Reference-Cited by-同舟云学术

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A

Published:2018-11 Issue:11 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Asante-Appiah Ernest¹,Liu Rong¹,Curry Stephanie¹,McMonagle Patricia¹,Agrawal Sony²,Carr Donna²,Rokosz Laura²,Lahser Frederick¹^ORCID,Bystol Karin¹,Chase Robert¹,Black Stuart¹,Ferrari Eric¹,Ingravallo Paul¹,Tong Ling³,Yu Wensheng³,Kozlowski Joseph³

Affiliation:

1. Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, New Jersey, USA

2. Department of In Vitro Pharmacology, Merck & Co., Inc., Kenilworth, New Jersey, USA

3. Department of Medicinal Chemistry, Merck & Co., Inc., Kenilworth, New Jersey, USA

Abstract

Inhibition of NS5A has emerged as an attractive strategy to intervene in hepatitis C virus (HCV) replication. Ruzasvir (formerly MK-8408) was developed as a novel NS5A inhibitor to improve upon the potency and barrier to resistance of early compounds.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01280-18

Reference69 articles.

1. WHO. 2017. Global hepatitis report 2017. World Health Organization Geneva Switzerland. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 15 March 2018.

2. Hepatitis C and liver transplantation

3. Sustained Virologic Response to Daclatasvir and Sofosbuvir, with or without Ribavirin, among Patients in the French Daclatasvir ATU Programme Infected with HCV Genotypes 4, 5 and 6

4. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study

5. The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tandem construction of biological relevant aliphatic 5-membered N-heterocycles;European Journal of Medicinal Chemistry;2022-05

2. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance;Frontiers in Cellular and Infection Microbiology;2020-06-30